Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 5/20 | 0.47 |
| ▸ | RAB9A | P51151 | 4/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | GABRA1 | P14867 | 8/20 | 0.47 |
| ▸ | GABRG2 | P18507 | 8/20 | 0.47 |
| ▸ | GABRB3 | P28472 | 8/20 | 0.47 |
| ▸ | GABRA5 | P31644 | 8/20 | 0.47 |
| ▸ | GABRA3 | P34903 | 8/20 | 0.47 |
| ▸ | GABRA2 | P47869 | 8/20 | 0.47 |
| ▸ | GABRA4 | P48169 | 7/20 | 0.47 |
| ▸ | GABRA6 | Q16445 | 7/20 | 0.47 |
| ▸ | GABRP | O00591 | 6/20 | 0.47 |
| ▸ | GABRD | O14764 | 6/20 | 0.47 |
| ▸ | GABRB1 | P18505 | 6/20 | 0.47 |
| ▸ | GABRB2 | P47870 | 6/20 | 0.47 |
| ▸ | GABRE | P78334 | 6/20 | 0.47 |
| ▸ | GABRG1 | Q8N1C3 | 6/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22605750 | 0.89 | NPC1 (0.52) | CYP1A2MAPTRAB9ASMN1; SMN2HSP90AA1 | |
| SCHEMBL21623015 | 0.87 | AR (0.49) | MAPTRAB9ASMN1; SMN2NOS1NOS2 | |
| SCHEMBL25002909 | 0.84 | RAB9A (0.49) | CYP1A2MAPTRAB9ASMN1; SMN2HSP90AA1 | |
| SCHEMBL23327392 | 0.83 | MAPT (0.52) | CYP1A2MAPTRAB9ASMN1; SMN2GABRA1 | |
| SCHEMBL29930605 | 0.83 | MAPT (0.52) | CYP1A2MAPTRAB9ASMN1; SMN2GABRA1 | |
| SCHEMBL27028360 | 0.83 | KDM4E (0.46) | CYP1A2MAPTRAB9ASMN1; SMN2NOS1 | |
| SCHEMBL27639521 | 0.83 | KDM4E (0.52) | CYP1A2MAPTRAB9ASMN1; SMN2NPC1 | |
| SCHEMBL127699 | 0.83 | CYP1A2 (0.53) | CYP1A2MAPTRAB9ASMN1; SMN2GABRA1 | |
| SCHEMBL7443662 | 0.82 | CYP1A2 (0.46) | CYP1A2MAPTRAB9ASMN1; SMN2HSP90AA1 | |
| SCHEMBL27028348 | 0.81 | NOS1 (0.45) | MAPTRAB9ASMN1; SMN2HSP90AA1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250115629-A1 | CHIRAL SYNTHONS FOR THE SYNTHESIS OF CHIRAL PHOSPHOROTHIOATES | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2025-04-10 | — | — | US | disclosed |
| US-20240067610-A1 | INHIBITORS OF NLRP3 INFLAMMASOME | BioAge Labs, Inc. | 2024-02-29 | — | — | US | disclosed |
| US-20240067610-A1 | INHIBITORS OF NLRP3 INFLAMMASOME | BioAge Labs, Inc. | 2024-02-29 | — | — | US | disclosed |
| EP-4308580-A1 | CHIRAL SYNTHONS FOR THE SYNTHESIS OF CHIRAL PHOSPHOROTHIOATES | Boehringer Ingelheim International GmbH (DE) | 2024-01-24 | — | — | EP | disclosed |
| US-20230365507-A1 | INHIBITORS OF NLRP3 INFLAMMASOME | BioAge Labs, Inc. | 2023-11-16 | — | — | US | disclosed |
| US-11702391-B2 | Inhibitors of NLRP3 inflammasome | BioAge Labs, Inc. (US) | 2023-07-18 | — | — | US | disclosed |
| US-11702391-B2 | Inhibitors of NLRP3 inflammasome | BioAge Labs, Inc. (US) | 2023-07-18 | — | — | US | disclosed |
| US-20230062119-A1 | USE OF BIOMARKERS IN IDENTIFYING PATIENTS THAT WILL BE RESPONSIVE TO TREATMENT WITH A PRMT5 INHIBITOR | MERCK SHARP & DOHME LLC (US) | 2023-03-02 | — | — | US | disclosed |
| US-20230062119-A1 | USE OF BIOMARKERS IN IDENTIFYING PATIENTS THAT WILL BE RESPONSIVE TO TREATMENT WITH A PRMT5 INHIBITOR | MERCK SHARP & DOHME LLC (US) | 2023-03-02 | — | — | US | disclosed |
| WO-2022194924-A1 | CHIRAL SYNTHONS FOR THE SYNTHESIS OF CHIRAL PHOSPHOROTHIOATES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2022-09-22 | — | — | WO | disclosed |
| EP-1383857-B1 | USE OF METAL COMPLEX COMPOUNDS AS OXIDATION CATALYSTS | CIBA SC HOLDING AG (CH) | 2006-05-31 | — | — | EP | disclosed |
| WO-2006045096-A2 | FLAVANOIDS AND ISOFLAVANOIDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | RESVERLOGIX CORP. (CA) | 2006-04-27 | — | — | WO | disclosed |
| US-20060019853-A1 | Use of metal complex compounds as catalysts for oxidation using molecular oxygen or air | CIBA SPECIALTY CHEMICALS CORP. | 2006-01-26 | — | — | US | disclosed |
| WO-2005068075-A1 | USE OF A COMPOSITION COMPRISING METAL COMPLEX COMPOUNDS AND POLYPHOSPHONATES AS CATALYSTS FOR OXIDATIONS | CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) | 2005-07-28 | — | — | WO | disclosed |
| WO-2005068074-A2 | USE OF METAL COMPLEX COMPOUNDS COMPRISING PYRIDINE PRYIMIDINE OR S-TRIAZNE DERIVED LIGANDS AS CATALYSTS FOR OXIDATIONS WITH ORGANIC PEROXY ACIDS AND/OR PRECURSORS OF ORGANIC PEROXY ACID AND H2O2 | CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) | 2005-07-28 | — | — | WO | disclosed |
| EP-1556468-A1 | USE OF METAL COMPLEX COMPOUNDS AS CATALYSTS FOR OXIDATION USING MOLECULAR OXYGEN OR AIR | Ciba SC Holding AG (CH) | 2005-07-27 | — | — | EP | disclosed |
| US-20040142843-A1 | Use of metal complex compounds as oxidation catalysts | CIBA SPECIALTY CHEMICALS CORP. | 2004-07-22 | — | — | US | disclosed |
| WO-2004039933-A1 | USE OF METAL COMPLEX COMPOUNDS AS CATALYSTS FOR OXIDATION USING MOLECULAR OXYGEN OR AIR | CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) | 2004-05-13 | — | — | WO | disclosed |
| EP-1383857-A2 | USE OF METAL COMPLEX COMPOUNDS AS OXIDATION CATALYSTS | Ciba SC Holding AG (CH) | 2004-01-28 | — | — | EP | disclosed |
| WO-2002088289-A2 | USE OF METAL COMPLEX COMPOUNDS AS OXIDATION CATALYSTS | CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) | 2002-11-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060019853-A1 | Use of metal complex compounds as catalysts for oxidation using molecular oxygen or air | COX14, MICOS13, OR10J3 | CYP1A2 509/4885MAPT 4366/4885RAB9A 2003/4885 |
| US-20240067610-A1 | INHIBITORS OF NLRP3 INFLAMMASOME | NLRP3, PYCARD, CASP1 | CYP1A2 4372/4885MAPT 432/4885RAB9A 3974/4885 |
| US-20250115629-A1 | CHIRAL SYNTHONS FOR THE SYNTHESIS OF CHIRAL PHOSPHOROTHIOATES | TYMP, RNGTT, TYMS | CYP1A2 4217/4885MAPT 1913/4885RAB9A 4055/4885 |
| US-11702391-B2 | Inhibitors of NLRP3 inflammasome | NLRP3, CASP1, PYCARD | CYP1A2 3857/4885MAPT 613/4885RAB9A 3916/4885 |
| US-20230365507-A1 | INHIBITORS OF NLRP3 INFLAMMASOME | NLRP3, PYCARD, CASP1 | CYP1A2 4372/4885MAPT 432/4885RAB9A 3974/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.